• Je něco špatně v tomto záznamu ?

Tumor Suppressor miR-34a: Potential Biomarker of TACE Response in HCC

J. Zavadil, J. Juracek, B. Cechova, T. Rohan, J. Husty, O. Slaby, M. Litschmannova, M. Uher, SN. Goldberg, T. Andrasina

. 2025 ; 48 (1) : 26-37. [pub] 20241205

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010450

Grantová podpora
MUNI/A/1222/2022 Masarykova Univerzita
16-31765A Ministerstvo Zdravotnictví Ceské Republiky
16-31314A Ministerstvo Zdravotnictví Ceské Republiky
65269705 Ministerstvo Zdravotnictví Ceské Republiky
SP2023/011 Vysoká Škola Bánská - Technická Univerzita Ostrava

PURPOSE: TACE induces variable systemic effects by producing factors that promote inflammation, oncogenesis, and angiogenesis. Here we compare concentrations of microRNAs (miR-21, miR-210 and miR-34a) and vascular endothelial growth factor (VEGF) in hepatocellular carcinoma (HCC) patients undergoing TACE with degradable (DSM) and nondegradable (DEB) particles and potential use of these biomarker changes for prediction of patient outcomes. MATERIALS AND METHODS: Overall, 52 patients with HCC treated with DSM TACE (24 patients) and DEB TACE (28 patients) were included in this prospective study. Concentrations of studied biomarkers were measured from blood plasma preprocedurally, immediately (< 90 min) postprocedurally, and 24-h after TACE. Levels were compared between DSM and DEB TACE and correlated with treatment response six and 12 months after the first TACE. RESULTS: Both DSM and DEB TACE elevated plasma levels of miR-21, miR-34a, and miR-210 at 24 h post-procedure compared to baseline levels (FC 1.25-4.0). MiR-34a elevation immediately after TACE was significantly associated with nonprogressive disease compared to those with progressive disease at both six months (FCa: p = 0.014) and 12 months (FCa: p = 0.029) post-TACE. No significant biomarker changes were found between the embolization particle groups. However, VEGF levels showed a decrease only in the DSM TACE group (FC24: p = < 0.001). CONCLUSION: Embolization particle type did not significantly impact miRNA or VEGF changes post-TACE. However, miR-34a elevation immediately after the procedure predicts better patient outcome and may prove useful as a biomarkers for the monitoring of clinical outcomes. LEVEL OF EVIDENCE: Level 3 Prospective cohort study.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010450
003      
CZ-PrNML
005      
20250429134535.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00270-024-03908-5 $2 doi
035    __
$a (PubMed)39638971
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zavadil, Jan $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Jihlavská 340/20, 625 00, Brno, Czechia
245    10
$a Tumor Suppressor miR-34a: Potential Biomarker of TACE Response in HCC / $c J. Zavadil, J. Juracek, B. Cechova, T. Rohan, J. Husty, O. Slaby, M. Litschmannova, M. Uher, SN. Goldberg, T. Andrasina
520    9_
$a PURPOSE: TACE induces variable systemic effects by producing factors that promote inflammation, oncogenesis, and angiogenesis. Here we compare concentrations of microRNAs (miR-21, miR-210 and miR-34a) and vascular endothelial growth factor (VEGF) in hepatocellular carcinoma (HCC) patients undergoing TACE with degradable (DSM) and nondegradable (DEB) particles and potential use of these biomarker changes for prediction of patient outcomes. MATERIALS AND METHODS: Overall, 52 patients with HCC treated with DSM TACE (24 patients) and DEB TACE (28 patients) were included in this prospective study. Concentrations of studied biomarkers were measured from blood plasma preprocedurally, immediately (< 90 min) postprocedurally, and 24-h after TACE. Levels were compared between DSM and DEB TACE and correlated with treatment response six and 12 months after the first TACE. RESULTS: Both DSM and DEB TACE elevated plasma levels of miR-21, miR-34a, and miR-210 at 24 h post-procedure compared to baseline levels (FC 1.25-4.0). MiR-34a elevation immediately after TACE was significantly associated with nonprogressive disease compared to those with progressive disease at both six months (FCa: p = 0.014) and 12 months (FCa: p = 0.029) post-TACE. No significant biomarker changes were found between the embolization particle groups. However, VEGF levels showed a decrease only in the DSM TACE group (FC24: p = < 0.001). CONCLUSION: Embolization particle type did not significantly impact miRNA or VEGF changes post-TACE. However, miR-34a elevation immediately after the procedure predicts better patient outcome and may prove useful as a biomarkers for the monitoring of clinical outcomes. LEVEL OF EVIDENCE: Level 3 Prospective cohort study.
650    _2
$a lidé $7 D006801
650    12
$a hepatocelulární karcinom $x terapie $x krev $x genetika $7 D006528
650    12
$a nádory jater $x terapie $x genetika $x krev $7 D008113
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a mikro RNA $x krev $7 D035683
650    _2
$a prospektivní studie $7 D011446
650    12
$a chemoembolizace $x metody $7 D016461
650    12
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a lidé středního věku $7 D008875
650    12
$a vaskulární endoteliální růstový faktor A $x krev $7 D042461
650    _2
$a senioři $7 D000368
650    _2
$a výsledek terapie $7 D016896
650    _2
$a biologické markery $x krev $7 D015415
655    _2
$a časopisecké články $7 D016428
700    1_
$a Juracek, Jaroslav $u Central European Institute of Technology, Kamenice 753/5, 625 00, Brno, Czechia $u CERIT-SC Centre, Institute of Computer Science, Masaryk University, Šumavská 416/15, 602 00, Brno, Czechia
700    1_
$a Cechova, Barbora $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Jihlavská 340/20, 625 00, Brno, Czechia
700    1_
$a Rohan, Tomas $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Jihlavská 340/20, 625 00, Brno, Czechia
700    1_
$a Husty, Jakub $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Jihlavská 340/20, 625 00, Brno, Czechia
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology, Kamenice 753/5, 625 00, Brno, Czechia
700    1_
$a Litschmannova, Martina $u Department of Applied Mathematics, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, 17. Listopadu 2172/15, 708 00, Ostrava, Czechia
700    1_
$a Uher, Michal $u Masaryk Memorial Cancer Institute, Žlutý Kopec 543/7, 602 00, Brno, Czechia
700    1_
$a Goldberg, S Nahum $u Hadassah Hebrew University Medical Center, Ein Karem, Jerusalem, Israel
700    1_
$a Andrasina, Tomas $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Jihlavská 340/20, 625 00, Brno, Czechia. andrasina.tomas@fnbrno.cz $1 https://orcid.org/0000000157235175 $7 xx0074370
773    0_
$w MED00001056 $t Cardiovascular and interventional radiology $x 1432-086X $g Roč. 48, č. 1 (2025), s. 26-37
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39638971 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134530 $b ABA008
999    __
$a ok $b bmc $g 2311667 $s 1247531
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 48 $c 1 $d 26-37 $e 20241205 $i 1432-086X $m Cardiovascular and interventional radiology $n Cardiovasc Intervent Radiol $x MED00001056
GRA    __
$a MUNI/A/1222/2022 $p Masarykova Univerzita
GRA    __
$a 16-31765A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a 16-31314A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a 65269705 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a SP2023/011 $p Vysoká Škola Bánská - Technická Univerzita Ostrava
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace